These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 6739312)

  • 41. [Clinical evaluation of BRL 25000 (clavulanic acid-amoxicillin) in the fields of obstetrics and gynecology].
    Kishida H; Kisaka Y; Matsubayashi S; Hiraoka H; Naitoh H; Tanaka S; Urabe T; Fujiwara A
    Jpn J Antibiot; 1983 Mar; 36(3):487-99. PubMed ID: 6553605
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changing role of co-trimoxazole in the treatment of recurrent urinary infections: a comparison with augmentin.
    Brumfitt W; Hamilton-Miller JM
    Br J Clin Pract; 1985 Sep; 39(9):346-51. PubMed ID: 3904797
    [No Abstract]   [Full Text] [Related]  

  • 43. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Urinary tract infections in children. Status in a pediatric hospital and sensitivity of bacterial strains to amoxycillin-clavulanic acid combination].
    Cochat N; Barbe G; Boutin-Tranchant ME; Cochat P
    Pediatrie; 1987; 42(4):309-14. PubMed ID: 3671031
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bacteriologic failure of amoxicillin-clavulanate in treatment of acute otitis media caused by nontypeable Haemophilus influenzae.
    Patel JA; Reisner B; Vizirinia N; Owen M; Chonmaitree T; Howie V
    J Pediatr; 1995 May; 126(5 Pt 1):799-806. PubMed ID: 7752010
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic studies of amoxicillin, potassium clavulanate and their combination.
    Witkowski G; Lode H; Höffken G; Koeppe P
    Eur J Clin Microbiol; 1982 Aug; 1(4):233-7. PubMed ID: 7173186
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Experimental and clinical studies on BRL 25000 (clavulanic acid-amoxicillin) in the field of obstetrics and gynecology].
    Cho N; Fukunaga K; Kunii K
    Jpn J Antibiot; 1983 Mar; 36(3):481-6. PubMed ID: 6876360
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Treatment of urinary infection with a combination of amoxycillin and clavulanic acid].
    Vránková J; Kocvara R
    Cas Lek Cesk; 1983 Sep; 122(37):1144-5. PubMed ID: 6627336
    [No Abstract]   [Full Text] [Related]  

  • 49. Further data on augmentin and co-trimoxazole in the treatment of urinary tract infection.
    Matts SG; Fancourt GJ; Mitchell CJ; Gowers E; Boston PF
    Br J Clin Pract; 1985 May; 39(5):179-84. PubMed ID: 3907682
    [No Abstract]   [Full Text] [Related]  

  • 50. [Combinations of beta-lactamase inhibitors and semisynthetic penicillins: amoxycillin/clavulanic acid (augmentin, amox-clav ), thycarcillin/clavulanic acid (thymentin). Action and usage].
    Fomina IP
    Antibiot Khimioter; 1997; 42(12):29-32. PubMed ID: 9480651
    [No Abstract]   [Full Text] [Related]  

  • 51. Clavulanate-potentiated amoxycillin: in vitro antibacterial activity and oral bioavailability in calves.
    Soback S; Bor A; Kurtz B; Paz R; Ziv G
    J Vet Pharmacol Ther; 1987 Jun; 10(2):105-13. PubMed ID: 3302313
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multi-investigator evaluation of the efficacy and safety of cefprozil, amoxicillin-clavulanate, cefixime and cefaclor in the treatment of acute otitis media.
    Kafetzis DA
    Eur J Clin Microbiol Infect Dis; 1994 Oct; 13(10):857-65. PubMed ID: 7889960
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chromosomally mediated intrinsic resistance to penicillin of penicillinase producing strains of Neisseria gonorrhoeae isolated in Sydney: guide to treatment with Augmentin.
    Tapsall JW; Phillips EA; Morris LM
    Genitourin Med; 1987 Oct; 63(5):305-8. PubMed ID: 3119461
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential sensitivities to amoxycillin/clavulanate and amoxycillin in general practice urinary infections.
    Brumfitt W; Hamilton-Miller JM
    Lancet; 1983 Sep; 2(8349):566. PubMed ID: 6136712
    [No Abstract]   [Full Text] [Related]  

  • 55. Bactericidal activity of BMY-28100 versus amoxicillin/clavulanic acid against Branhamella catarrhalis.
    Yourassowsky E; Van der Linden MP; Lismont MJ; Crokaert F
    Eur J Clin Microbiol Infect Dis; 1988 Jun; 7(3):433-4. PubMed ID: 3137055
    [No Abstract]   [Full Text] [Related]  

  • 56. [Experimental and clinical studies on BRL 25000 (clavulanic acid-amoxicillin) granules in the pediatric field].
    Sunakawa K; Ishizuka Y
    Jpn J Antibiot; 1985 Feb; 38(2):319-26. PubMed ID: 3892075
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Augmentin: laboratory studies.
    Farrell ID; Turner PJ
    Scott Med J; 1982; 27 Spec No.():S21-3. PubMed ID: 6762661
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibacterial activity of ticarcillin in the presence of clavulanate potassium.
    Sutherland R; Beale AS; Boon RJ; Griffin KE; Slocombe B; Stokes DH; White AR
    Am J Med; 1985 Nov; 79(5B):13-24. PubMed ID: 3878080
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In-vitro sensitivity of amoxicillin/clavulanic acid (Augmentin) to isolated beta-lactamases and in-vitro antibacterial activity.
    Esposito S; Noviello S
    J Chemother; 1990 Jun; 2(3):167-70. PubMed ID: 2380766
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [In vitro susceptibilities of causative organisms isolated from patients with primary respiratory tract infections to BRL 25000 (clavulanic acid/amoxicillin)].
    Deguchi K; Fukayama S; Nishimura Y; Yokota N; Tanaka S; Oda S; Matsumoto Y; Ikegami R; Sato K; Fukumoto T
    Jpn J Antibiot; 1985 Oct; 38(10):2797-808. PubMed ID: 3878415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.